Supplementary Table 2 Summary of adverse events (safety set)

Number of Subjects With	0.1 mg/kg GX-H9 weekly (N=11) n (%) [E]	0.3 mg/kg GX-H9 EOW (N=12) n (%) [E]	0.2 mg/kg GX-H9 EOW (N=12) n (%) [E]	6 μg/kg Genotropin® daily (N=9) n (%) [E]
Any AE	5 (45.5) [12]	9 (75.0) [23]	7 (58.3) [13]	7 (77.8) [9]
Any TEAE	5 (45.5) [12]	9 (75.0) [20]	6 (50.0) [10]	7 (77.8) [8]
Any serious TEAE	0	0	0	0
Any study drug-related TEAE	1 (9.1) [3]	2 (16.7) [3]	3 (25.0) [4]	2 (22.2) [2]
Dizziness	0	0	2	0
Hepatic enzyme increased	0	0	0	1
Headache	1	0	0	0
Injection site pain	1	0	0	0
Injection site erythema	0	0	1	0
Myositis	0	0	0	1
Myalgia	0	1	0	0
Arthralgia	1	0	0	0
Edema peripheral	0	1	0	0
Paresthesia	0	1	0	0
Lipohypertrophy	0	0	1	0
Any study drug-related serious TEAE	0	0	0	0
Any TEAE leading to treatment discontinuation	0	0	0	1 (11.1) [1]
Any AE leading to death	0	0	0	0

Notes: Subjects were counted only once; however, subjects were counted more than once if they reported more than 1 AE in each category.

Abbreviations: AE, adverse event; EOW, every other week; TEAE, treatment-emergent adverse event; n, number of subjects; N, total number of subjects in treatment group; [E], number of events.